Generic name: emtricitabine 200mg, tenofovir alafenamide fumarate 25mg
Dosage form: tablet
Medically reviewed on October 6, 2017.
Testing Prior to Initiation of DESCOVY
Prior to initiation of DESCOVY, patients should be tested for hepatitis B virus infection [see Warnings and Precautions (5.1)].
Estimated creatinine clearance, urine glucose, and urine protein should be assessed before initiating DESCOVY therapy and should be monitored during therapy in all patients [see Warnings and Precautions (5.3)].
DESCOVY is a two-drug fixed dose combination product containing 200 mg of emtricitabine (FTC) and 25 mg of tenofovir alafenamide (TAF). The recommended dosage of DESCOVY is one tablet taken orally once daily with or without food in adults and pediatric patients with body weight at least 25 kg and creatinine clearance greater than or equal to 30 mL per minute [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].
For specific dosing recommendations for coadministered third agents, refer to their respective prescribing information [see Drug Interactions (7)]. The safety and effectiveness of DESCOVY coadminstered with an HIV-1 protease inhibitor that is administered with either ritonavir or cobicistat have not been established in pediatric subjects weighing less than 35 kg.
More about Descovy (emtricitabine / tenofovir alafenamide)
- Descovy Side Effects
- During Pregnancy
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- 3 Reviews
- Drug class: antiviral combinations